The current market requires both innovation and growth to drive the creation of new biologics. At ALLOZYNE, we demonstrate this through both of our technology platforms as well as across our pipeline to target key disease areas. Both of our platforms enable the incorporation of amino acid analogues at any position to create biologics that elicit improved efficacy, tolerability and pharmacology.
View Top Employees from ALLOZYNEWebsite | http://www.allozyne.com |
Revenue | $11 million |
Funding | $7 million |
Employees | 3 (2 on RocketReach) |
Founded | 2005 |
Address | 1600 Fairview Ave E Suite 300, Seattle, Washington 98102, US |
Phone | (206) 518-5700 |
Fax | (206) 518-5799 |
Technologies | |
Industry | Biotechnology, Pharmaceuticals, Biotechnology Research, Site-Specific Bioconjugation, Science and Engineering, Drug Discovery, Oncology, Healthcare, Health Care, Antibody-Drug Conjugates, Therapeutics, Autoimmunity & Inflammation |
Competitors | Acucela Inc., Clearside Biomedical, Inc., InSite Vision, Inc., Omeros Corporation, Receptos, a wholly-owned subsidiary of Celgene |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular ALLOZYNE employee's phone or email?
The ALLOZYNE annual revenue was $11 million in 2024.
Kenneth Grabstein is the Chief Scientific Officer of ALLOZYNE.
2 people are employed at ALLOZYNE.
ALLOZYNE is based in Seattle, Washington.
The NAICS codes for ALLOZYNE are [54, 541, 5417].
The SIC codes for ALLOZYNE are [873, 87].